Related Experiment Video

Updated: Dec 16, 2025

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

12.9K

Epigenetic targeting in lymphoma

Stephen Booth1, Graham Collins2

  • 1Early Phase Clinical Trials Unit, Department of Oncology, University of Oxford, Oxford, UK.

British Journal of Haematology
|July 2, 2020
PubMed

Insights

Epigenetic alterations are crucial in lymphoma development. This review covers epigenetic modifying agents for lymphoma, examining their efficacy and ongoing clinical trials for relapsed or refractory cases.

Area of Science:

  • Hematology
  • Oncology
  • Epigenetics

Background:

  • Lymphoid malignancies, including lymphomas, present a significant clinical challenge, particularly in relapsed or refractory settings.
  • Despite treatment advances, patient prognosis in these advanced stages often remains poor.
  • Epigenetic alterations are increasingly recognized as key drivers in the pathogenesis of lymphoid cancers.

Purpose of the Study:

  • To review the critical role of epigenetic modifications in lymphoma biology.
  • To summarize the clinical experience with epigenetic modifying agents across different lymphoma subtypes.
  • To discuss current and future clinical studies involving these agents for lymphoma treatment.

Main Methods:

  • Literature review of published studies on epigenetic alterations in lymphoma.
  • Analysis of clinical trial data for epigenetic modifying agents in various lymphoma subtypes.
  • Synthesis of information on ongoing clinical investigations.

Main Results:

  • Epigenetic modifications are integral to the development and progression of lymphomas.
  • Epigenetic modifying agents have shown variable efficacy in clinical studies, dependent on lymphoma subtype.
  • Several ongoing clinical trials are evaluating novel epigenetic therapies for lymphoma.

Conclusions:

  • Epigenetic modifications represent a promising therapeutic target in lymphoid malignancies.
  • Further research and clinical trials are essential to optimize the use of epigenetic agents in lymphoma treatment.
  • Targeting epigenetic alterations offers potential for improved outcomes in relapsed or refractory lymphoma patients.
Keywords:
clinical trialsepigeneticslymphoid malignancies

More Related Videos

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients13:21

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients

Published on: June 16, 2017

10.4K
A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

7.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.6K
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
33.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K